Previous 10 | Next 10 |
Today, we want to share our analysis of Bellicum Pharmaceuticals ( BLCM ) with you. Over the last year, its stock largely fluctuated, falling from ~ $7 in September 2018 to $0.78 in August 2019. Recently, the company’s stock price grew by more than 20% after Baker Bros. disclosed its ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Editor's note: Seeking Alpha is proud to welcome GG Pharma Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » TrovaGene, I...
Pixabay Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical ...
Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD bluebird bio, Inc. (Nasdaq: BLUE) announced that updated data from the clinical development program for...
bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14 th Annual Biotech Conference, Wednesday, September 4, at 8:00 a.m. ET at the Four Seasons Boston, Boston, MA Mor...
Genmab A/S (NASDAQ: GMAB ) initiated with Overweight rating and $30 (58% upside) price target at Morgan Stanley. Initiated with Outperform rating and $23 price target at RBC. Shares up 1% premarket. More news on: Genmab A/S, Fulcrum Therapeutics, Inc., Mirum Pharmaceuticals, In...
bluebird bio (NASDAQ: BLUE ): Q2 GAAP EPS of -$3.55 misses by $0.48 . More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...